Home Newsfeeds HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $32 Price Target

HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $32 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $32 price target.

byBenzinga Newsdesk

February 17, 2023

1 minute read

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $32 price target.

Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed

By Lara Goldstein

December 14, 3:26 PM

Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no additional therapeutic intervention, in Generalized Anxi

MNMD

Goldman Sachs Maintains Buy on Grocery Outlet Holding, Lowers Price Target to $34

By Benzinga Newsdesk

March 1, 8:37 AM

Goldman Sachs analyst Kate McShane maintains Grocery Outlet Holding (NASDAQ:GO) with a Buy and lowers the price target from $38 to $34.

Morgan Stanley Maintains Overweight on Vistra, Lowers Price Target to $30

By Benzinga Newsdesk

February 22, 1:27 PM

Morgan Stanley analyst Stephen Byrd maintains Vistra (NYSE:VST) with a Overweight and lowers the price target from $31 to $30.

VST

Truist Securities Maintains Buy on Equifax, Lowers Price Target to $230

By Benzinga Newsdesk

July 22, 9:15 AM

Truist Securities analyst Andrew Jeffrey maintains Equifax (NYSE:EFX) with a Buy and lowers the price target from $250 to $230.

EFX

HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $32 Price Target

Related Posts

Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed

Goldman Sachs Maintains Buy on Grocery Outlet Holding, Lowers Price Target to $34

Morgan Stanley Maintains Overweight on Vistra, Lowers Price Target to $30

Truist Securities Maintains Buy on Equifax, Lowers Price Target to $230